MX2021002456A - Nuevos derivados de tiazol y sus sales farmaceuticamente aceptables. - Google Patents

Nuevos derivados de tiazol y sus sales farmaceuticamente aceptables.

Info

Publication number
MX2021002456A
MX2021002456A MX2021002456A MX2021002456A MX2021002456A MX 2021002456 A MX2021002456 A MX 2021002456A MX 2021002456 A MX2021002456 A MX 2021002456A MX 2021002456 A MX2021002456 A MX 2021002456A MX 2021002456 A MX2021002456 A MX 2021002456A
Authority
MX
Mexico
Prior art keywords
pharmaceutically acceptable
acceptable salts
thiazole derivatives
novel thiazole
cdk
Prior art date
Application number
MX2021002456A
Other languages
English (en)
Inventor
Kwang Ok Lee
Jun Hee Lee
Mijung Lee
Jakyung Yoo
Kangwoo Lee
Jieun Min
Original Assignee
Yungjin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yungjin Pharmaceutical Co Ltd filed Critical Yungjin Pharmaceutical Co Ltd
Publication of MX2021002456A publication Critical patent/MX2021002456A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La presente invención proporciona un nuevo derivado de tiazol o una sal farmacéuticamente aceptable de éste y un método para prepararlo. El derivado de tiazol o una sal farmacéuticamente aceptable de éste, de acuerdo con la presente invención, tiene una actividad inhibidora selectiva contra la cinasa dependiente de ciclina (CDK) y, por lo tanto, puede usarse de manera útil como un agente preventivo o terapéutico para diversas enfermedades asociadas con la CDK.
MX2021002456A 2018-09-17 2019-09-11 Nuevos derivados de tiazol y sus sales farmaceuticamente aceptables. MX2021002456A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20180111001 2018-09-17
PCT/KR2019/011887 WO2020060112A1 (en) 2018-09-17 2019-09-11 Novel thiazole derivatives and pharmaceutically acceptable salts thereof

Publications (1)

Publication Number Publication Date
MX2021002456A true MX2021002456A (es) 2021-06-15

Family

ID=69887568

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002456A MX2021002456A (es) 2018-09-17 2019-09-11 Nuevos derivados de tiazol y sus sales farmaceuticamente aceptables.

Country Status (19)

Country Link
US (1) US20210284658A1 (es)
EP (1) EP3853225B1 (es)
JP (1) JP7235859B2 (es)
KR (2) KR102130253B1 (es)
CN (1) CN112739695A (es)
AU (1) AU2019344240B2 (es)
BR (1) BR112021004999A2 (es)
CA (1) CA3106855A1 (es)
CL (1) CL2021000594A1 (es)
CO (1) CO2021003412A2 (es)
EA (1) EA202190558A1 (es)
IL (1) IL280639B (es)
MX (1) MX2021002456A (es)
PH (1) PH12021550572A1 (es)
SG (1) SG11202100531RA (es)
TW (1) TW202023548A (es)
UA (1) UA125427C2 (es)
WO (1) WO2020060112A1 (es)
ZA (1) ZA202101652B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102335637B1 (ko) * 2020-03-13 2021-12-06 영진약품 주식회사 신규한 cdk7 억제 화합물 및 이의 약제학적으로 허용가능한 염

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
ES2237919T4 (es) * 1998-06-18 2007-05-01 Bristol-Myers Squibb Company Inhibidores aminotiazol sustituidos con carbono de quinasas dependientes de ciclina.
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
EP1406899B1 (en) * 2001-07-19 2006-11-15 Pfizer Italia S.r.l. Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
BRPI0514515A (pt) * 2004-08-17 2008-06-10 Hoffmann La Roche hidantoìnas substituìdas
US20090264415A2 (en) * 2004-12-30 2009-10-22 Steven De Jonghe Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
US8183239B2 (en) * 2005-10-31 2012-05-22 Janssen Pharmaceutica Nv Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2008138755A2 (en) 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
AU2009314310A1 (en) * 2008-10-29 2010-05-20 Sirtris Pharmaceuticals, Inc. Pyridine, bicyclic pyridine and related analogs as sirtuin modulators
US9221773B2 (en) * 2009-12-22 2015-12-29 The Translational Genomics Research Institute Benzamide derivatives
WO2011084985A1 (en) * 2010-01-07 2011-07-14 Boehringer Ingelheim International Gmbh Cxcr3 receptor antagonists
US8404859B2 (en) 2011-03-16 2013-03-26 Hoffmann-La Roche Inc. Thiazole and thiophene compounds
WO2014063068A1 (en) 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CN105849099B (zh) 2013-10-18 2020-01-17 达纳-法伯癌症研究所股份有限公司 周期蛋白依赖性激酶7(cdk7)的多环抑制剂
EP2878339A1 (en) * 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3 antagonists
MX358346B (es) 2014-04-04 2018-08-15 Syros Pharmaceuticals Inc Inhibidores de la quinasa dependiente de ciclina 7 (cdk7).
CA2987552A1 (en) * 2015-06-04 2016-12-08 Aurigene Discovery Technologies Limited Substituted heterocyclyl derivatives as cdk inhibitors

Also Published As

Publication number Publication date
KR102130253B1 (ko) 2020-07-03
EP3853225A1 (en) 2021-07-28
JP7235859B2 (ja) 2023-03-08
SG11202100531RA (en) 2021-02-25
UA125427C2 (uk) 2022-03-02
CL2021000594A1 (es) 2021-12-03
CN112739695A (zh) 2021-04-30
PH12021550572A1 (en) 2021-10-25
AU2019344240B2 (en) 2022-09-29
IL280639A (en) 2021-03-25
AU2019344240A1 (en) 2021-02-25
KR20200032002A (ko) 2020-03-25
BR112021004999A2 (pt) 2021-06-08
CO2021003412A2 (es) 2021-04-08
EP3853225B1 (en) 2023-11-29
CA3106855A1 (en) 2020-03-26
KR20200078465A (ko) 2020-07-01
TW202023548A (zh) 2020-07-01
EA202190558A1 (ru) 2022-02-03
EP3853225A4 (en) 2022-06-15
US20210284658A1 (en) 2021-09-16
EP3853225C0 (en) 2023-11-29
IL280639B (en) 2022-07-01
ZA202101652B (en) 2022-07-27
WO2020060112A1 (en) 2020-03-26
JP2021535924A (ja) 2021-12-23

Similar Documents

Publication Publication Date Title
PH12019501688A1 (en) Pyridine derivative as ask1 inhibitor and preparation method and use thereof
PH12019500395A1 (en) Amino-pyrrolopyrimidinone compounds and methods of use thereof
SA518400547B1 (ar) مشتقات بيرازولو بيريميدين كمثبط كيناز
MX2022011029A (es) Compuestos de arilo, heteroarilo y heterociclicos para el tratamiento de trastornos medicos.
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
MX2017014645A (es) Profarmacos de alvocidib que tienen una biodisponibilidad aumentada.
CA2983481A1 (en) Janus kinase inhibitor
NZ739893A (en) Fused pyrimidine compound or salt thereof
MY202069A (en) Pharmaceutical composition
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
PH12017550004A1 (en) Heterocyclic derivatives and use thereof
WO2016126085A3 (ko) 헤테로 고리 화합물 및 그를 포함하는 약제학적 조성물
CA2914620C (en) Heterocyclic derivatives and use thereof
SA520411635B1 (ar) A2a مشتق حلقي مدمج كمثبط مستقبل
CR20190520A (es) Composiciones y compuestos terapéuticos y métodos para utilizarlos
MX2021007247A (es) Derivados de rapamicina.
MX2018011592A (es) Compuesto que tiene actividad inhibitoria de idh mutante, metodo de preparacion y usos del mismo.
MX2018008153A (es) Derivados de c-glicósido que tienen anillos de fenilo condensado o sales farmacéuticamente aceptables de los mismos, metodo para prepararlos y composición farmacéutica que los contiene.
PH12021550572A1 (en) Novel thiazole derivatives and pharmaceutically acceptable salts thereof
NZ727715A (en) Novel heterocyclic compounds having prs enzyme inhibitory effect
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
WO2016047967A3 (ko) N-(5-아릴아미도-2-메틸페닐)-5-메틸이소옥사졸-4-카복스아미드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 fms 키나아제 저해제
MX2020008273A (es) Inhibidores de la cinasa del complejo de activacion transcripcional notch ("nack") y metodos para el uso de los mismos.
WO2016089062A3 (en) Heterocyclic derivatives and use thereof